Clinical Trial Update: A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of YL-15293 in advanced solid tumors with KRAS G12C mutation is ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kras G12c-mutant Solid Tumor
• Solid Tumor

Drugs mentioned

• YL-15293

Snippet

Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd. | Conditions: Advanced Solid Tumor | Phase 1, Phase 2 | Status: UNKNOWN